The HIV/HBV/HCV test kits market size is projected to be valued at USD 6,568.3 million in 2023 and is expected to rise to USD 11,573.9 million by 2033. The sales of HIV/HBV/HCV test kits are expected to grow at a significant CAGR of 5.8% during the forecast period. Various trend positively influencing the HIV/HBV/HCV test kits market are:
A wide range of micro and macroeconomic factors are influencing the growth of the HIV/HBV/HCV test kits market. The most influential factor is the extensive awareness campaigns carried out by various non-governmental organizations around the world.
These non-governmental organizations are attempting to reach out to people in remote areas and educate them about immunodeficiency diseases and the methods for detecting and preventing them. This has resulted in a significant increase in global demand for HIV/HBV/HCV test kits.
One of the key development factors for the global HIV/HBV/HCV test kits market is rising demand for point-of-care testing for HIV, HBV, and HCV.
POC testing technologies are now more efficient, widely available, and reasonably priced. Early HIV detection can be extremely beneficial to the patient because it facilitates the doctor to design a more effective treatment plan.
Governments and regulating authorities all over the world have launched initiatives and campaigns to educate and treat people. They are supplying these kits for free in order to raise awareness.
Increasing investments by leading players to make these HIV/HBV/HCV test kits more efficient, reliable, and affordable has contributed to the global market's overall growth. The ease of use of these test kits has increased their popularity in medical centers and hospitals.
Regardless of the various factors influencing the growth of this market, there are several key issues that must be addressed in order to facilitate future growth. The relatively high total costs of developing and using HIV/HBV/HCV test kits, as well as reimbursement policies, are limiting the market's growth.
However, the market is expanding as a result of rising product approvals, alliances, and acquisitions by major companies.
| Attributes | Details |
|---|---|
| HIV/HBV/HCV Test Kits Market CAGR | 5.8 % |
| HIV/HBV/HCV Test Kits Market Valuation (2023) | USD 6,568.3 million |
| HIV/HBV/HCV Test Kits Market Valuation (2033) | USD 11,573.9 million 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Market Statistics | Details |
|---|---|
| H1,2021 (A) | 6.54% |
| H1,2022 Projected (P) | 6.44% |
| H1,2022 Outlook (O) | 6.24% |
| BPS Change: H1,2022 (O) - H1,2022 (P) | (-) 20 ↓ |
| BPS Change: H1,2022 (O) - H1,2021 (A) | (-) 30 ↓ |
The comparative analysis and market growth rate of global HIV/HBV/HCV test kits market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 20 BPS. Furthermore, a negative BPS growth is expected in H1-2022 over H1- 2021 duration with 30 Basis Point Share (BPS).
The decline in the BPs values observed can be attributed to the disruptions in supply chain and distribution networks globally due to the global pandemic. Moreover, the availability of self-test kits is limited to the developed nations, and thus poses a dip in demand, owed to the high disease epidemiology in the developing nations and the high demand generated through the same.
The key developments in the market include the launch of a real-time fluorescence PCR technology used for nucleic acid qualitative detection of HBV, and chip-based assays for HCV, such as the Truenat HCV.
Growing disease epidemiology of viral and infectious diseases, and the increasing efforts by regional governments to extend outreach for detection is anticipated to provide a positive growth outlook for the market during the projected period.
The world has seen significant increase in incidence of HIV and hepatitis, and this is expected to majorly drive HIV/HBV/HCV test kit consumption. With HIV and hepatitis infections being a major public health issue across the world, demand for efficient diagnostic services for these diseases is prominent.
Sales of HIV/HBV/HCV test kits rose at a CAGR of 6.8% from 2018 to 2022. Governments and NGOs across the world are taking initiatives to raise awareness about STD testing and its importance in the fight against HIV and hepatitis. This has led to substantial increase in awareness on a global level, with initiatives such as 'Start Talking. Stop HIV'.
Rising research & developments in the medical diagnostics industry, increasing incidence of HIV and hepatitis, increasing awareness among the general population, rising healthcare expenditure, technological advancements in diagnostics, etc., are some major factors that are expected to drive consumption of HIV/HBV/HCV test kits.
Demand for HIV/HBV/HCV test kits is expected to be majorly influenced by developing and emerging markets, with low- and middle-income countries such as Brazil, India, and China leading the way.
Lack of awareness and inadequate availability of test kits in less-developed economies is expected to restrain demand for HIV/HBV/HCV test kits to a certain extent. Market witnessed a significant downfall during the pandemic period as supply lines were cut short. Nevertheless, the market is anticipated to recover swiftly and contribute a USD 11,573.9 million revenue share by 2033.
Overall, the HIV/HBV/HCV test kits market is predicted to expand at a CAGR of 5.8% from 2023 to 2033.
Principal Consultant
Innovations and Product developments
The burden of HIV, HBV, and HCV infections is still disproportionately high in developing economies (India, sub-Saharan Africa, Brazil) where co-infection rates are high. For HIV, HBV, and HCV serological testing, high analytical performance multiplex rapid diagnostic techniques may improve the cascade of screening and lead to more cost-effective linkage to care. Such a testing strategy may be especially beneficial for hard-to-reach high-risk populations and may also increase the impact of self-testing on public health.
For instance, the prototype Triplex HIV/HCV/HBsAg finger-stick whole-blood self-test may provide a simple, quick, and inexpensive way to detect HIV, HBV, and HCV infections. It might be particularly useful for enhancing the detection of three closely related endemic viral diseases. These choices might boost screening programs, reducing the price of diseases brought on by untreated HIV, HBV, or HCV infections in the future. They might also help with efforts to treat these infections and perhaps even eradicate HCV infection.
Lack of Awareness to Hinder Sales of HIV Test Kits
Awareness about the treatment of HIV in less developed economies such as Brazil, India, and African nations is very limited due to lack of developed healthcare infrastructure. This has adversely affected HIV/HBV/HCV test kit sales in these economies and restrained overall market potential on a global level.
The asymptomatic nature of infections has also hampered the HIV/HBV/HCV test kits market. Poor healthcare facilities, high costs of treatments and medicines, and low STD testing are some other factors that may restrain HIV test kit sales over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
HIV has been a public health issue in the United States for quite some time, and while the number of new cases has decreased over the past decades, the rate of new infection detections remains a source of concern. Advanced healthcare infrastructure, increased patient awareness, and rising adoption of effective rapid testing kits are some of the major factors driving the HIV/HBV/HCV testing systems market in the United States.
| United States Market Size (USDmillion/billion) by End of Forecast Period (2033) | USD 3,455 million |
|---|---|
| United States Market Absolute Dollar Growth (USD million/billion) | USD 135.1 million |
| CAGR % 2017 to 2022 | 7.7% |
| CAGR % 2023 to End of Forecast (2033) | 5.9% |
Canada is expected to have a significant share due to advanced diagnostic tools, high awareness of disease and diagnostic devices, a strong presence of industry players in the region, improved healthcare infrastructure, and increased awareness among healthcare industry stakeholders about available technologies in the region. For example, the Public Health Agency of Canada investigated 28 cases of severe acute hepatitis in children in Canada that met the national case definition between April and September 2022. As a result, an increase in hepatitis cases is expected to lead to an increase in diagnostic testing, ultimately driving market growth in the region.
| Canada Market Size (USD million/billion) by End of Forecast Period (2033) | USD 479.0 million |
|---|---|
| Canada Market Absolute Dollar Growth (USD million/billion) | 21.70 million |
| CAGR % 2017 to 2022 | 9.1% |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The region's ever-increasing population is the primary driving factor for the market. China and India are two of the world's most densely populated countries in Asia Pacific. A dense population is more likely to be infected with an immunodeficiency virus. Naturally, awareness and availability of HIV/HBV/HCV test kits are expected to grow in the Asia Pacific market.
| China Market Size (USD million/billion) by End of Forecast Period (2033) | USD 1032.4 million |
|---|---|
| China Market Absolute Dollar Growth (USD million/billion) | USD 28.4 million |
| CAGR % 2017 to 2022 | 3.8% |
| CAGR % 2023 to End of Forecast (2033) | 5.5% |
India is the world's second-most populous country and ranks third in terms of HIV infections, with over 2 million people infected. Instances of new HIV infections have decreased in recent decades, but they remain a source of concern given the country's large population.
Increasing STD testing awareness and developing healthcare infrastructure are expected to have a significant impact on HIV/HBV/HCV test equipment demand in India. Over the next few years, the market in India is likely to remain extremely profitable for HIV/HBV/HCV test kit providers.
Segment to witness a growth of 6.4% during 2023 to 2033
In 2022, the assay-based test kits segment held the major share of the market. Assay kits are the first line of patients testing which is naturally stimulating its growth. Furthermore, in most developing countries, healthcare professionals and patients rely on assay-based testing results. Besides, there have been advancements in assay-based test kits. The Xpert HCV Viral Load Fingerstick Test from Cepheid, for example, is a point-of-care test that employs the GeneXpert System. This point-of-care test looks for HCV RNA in finger-stick whole blood capillaries (or assay). This type of HCV testing involves drawing capillary blood from the patient via finger prick into a Minivette collection device, which is then processed in a GeneXpert device at or near the point-of-care testing location.
Blood sample tops the sample segment and is expanding at a rapid rate of 6.1% CAGR during the forecast period.
Blood samples are highly prevalent in testing or diagnosis procedures due to ease in storing and their high reliability on patients sample profile. Most AIDS and AIDS-related complex (ARC) patients, as well as many asymptomatic individuals belonging to high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The presence of these HIV antibodies in human blood and plasma samples is frequently tested using enzyme-linked immunosorbent assays (ELISA). INNO-LIA HIV I/II Score, for example, is a Line Immuno Assay (LIA) that detects the presence of antibodies against HIV-1, including group O and HIV-2, in human blood or plasma. INNO-HIV LIA's I/II Score distinguishes between HIV-1 and HIV-2 infections. It is intended to be used in conjunction with an anti-HIV screening process on reactive specimens. As a result, demand for assay-based test kits has increased.
Given the presence of a few companies operating globally and regionally, the HIV/HBV/HCV test market is slightly fragmented. The competitive landscape includes an examination of a few well-known international and local companies that hold market share. Abbott Laboratories, Danaher Corporation, BioMerieux SA, Bio-Rad Laboratories Inc, Diasorin S.p.A, F. Hoffmann-La Roche AG, Hologic Inc, MedMira Inc, Qaigen Inc, Grifols SA, Sysmex Corporation, and Siemens Healthineers are key market players.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million for Value |
| Key Countries Covered | USA, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa |
| Key Segments Covered | Test Kit Type, Sample, End User, Region |
| Key Companies Profiled | BioMerieux SA; Bio-Rad Laboratories Inc; Diasorin S.p.A; F. Hoffmann-La Roche AG; Hologic Inc; MedMira Inc; Qaigen Inc; Grifols SA; Sysmex Corporation; and Siemens Healthineers |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The projected HIV/HBV/HCV test kits market size is expected to reach USD 6,568.3 million in 2023, with a forecasted surge to surpass USD 11,573.9 million by 2033.
The HIV/HBV/HCV test kits market recorded a 6.8% CAGR from 2018 to 2022.
The HIV/HBV/HCV test kits market expansion is propelled by heightened awareness, improved diagnostics accessibility, and global health initiatives.
Prominent challenges for HIV/HBV/HCV test kits market players include affordability barriers, limited healthcare infrastructure, and regulatory complexities.
HIV/HBV/HCV test kits are predominantly adopted in high-burden regions, including Southeast Asia and parts of Eastern Europe.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Kit Type 5.1. Assay-based Test Kits 5.2. Rapid Test Kits 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample 6.1. Blood 6.2. Urine 6.3. Saliva 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals 7.2. Clinics 7.3. Diagnostic Laboratories 7.4. Government Organizations and NGOs 7.5. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Hoffmann-La Roche Ltd. 16.2. Abbott Laboratories 16.3. bioMérieux SA 16.4. Bio-Rad Laboratories Inc. 16.5. QIAGEN 16.6. Hologic Inc. 16.7. Meridian Bioscience, Inc. 16.8. Siemens AG 16.9. Creative Diagnostics 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
HIV/HBV/HCV Test Kits Market
